Secukinumab: A Review in Ankylosing Spondylitis, PMID: 30793255
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial, PMID: 32386593
Safety of secukinumab in the treatment of psoriasis, PMID: 27545070
Secukinumab in plaque psoriasis--results of two phase 3 trials, PMID: 25007392
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, PMID: 26699169
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial, PMID: 32594522
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial, PMID: 31402114
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis, PMID: 26422723
Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature, PMID: 28732152
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study, PMID: 32770640
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data, PMID: 31046809
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 26135703
[Secukinumab], PMID: 31204124
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study, PMID: 30716404
Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies, PMID: 31919937
Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis, PMID: 30914343
Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis, PMID: 29285605
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study, PMID: 32479641
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study), PMID: 29444376
Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease, PMID: 31785165
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial, PMID: 26092291
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks, PMID: 30508547
The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond, PMID: 30576610
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study, PMID: 30590813
Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients, PMID: 31599476
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis, PMID: 31129129
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study, PMID: 27663079
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial, PMID: 33068444
IgA vasculitis during secukinumab therapy, PMID: 32860543
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study, PMID: 31102257
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), PMID: 32124442
Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5, PMID: 32925287
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS), PMID: 31983056
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY), PMID: 32365251
Safety of secukinumab for the treatment of active ankylosing spondylitis, PMID: 33470130
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3, PMID: 29273067
Secukinumab in the treatment of psoriasis: an update, PMID: 28162025
Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan, PMID: 33099791
Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study, PMID: 30148436
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study, PMID: 31565244
Secukinumab-Induced Delayed-Type Drug Hypersensitivity Reactions, PMID: 31220050
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review, PMID: 32591970
Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre, PMID: 32783092
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab, PMID: 31712178
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial, PMID: 30367462
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial, PMID: 31286480
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial, PMID: 27707593
Secukinumab (AIN457) for the treatment of psoriasis, PMID: 26428036
Secukinumab-associated localized granuloma annulare (SAGA): a case report and review of the literature, PMID: 32941717
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3), PMID: 29544534
For research use only. Not for human or drug use.
